FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033926666> ?p ?o ?g. }

• W2033926666 endingPage "1133.e1" @default.
• W2033926666 startingPage "1124" @default.
• W2033926666 abstract "BackgroundV(D)J recombination takes place during lymphocyte development to generate a large repertoire of T- and B-cell receptors. Mutations in recombination-activating gene 1 (RAG1) and RAG2 result in loss or reduction of V(D)J recombination. It is known that different mutations in RAG genes vary in residual recombinase activity and give rise to a broad spectrum of clinical phenotypes.ObjectiveWe sought to study the immunologic mechanisms causing the clinical spectrum of RAG deficiency.MethodsWe included 22 patients with similar RAG1 mutations (c.519delT or c.368_369delAA) resulting in N-terminal truncated RAG1 protein with residual recombination activity but presenting with different clinical phenotypes. We studied precursor B-cell development, immunoglobulin and T-cell receptor repertoire formation, receptor editing, and B- and T-cell numbers.ResultsClinically, patients were divided into 3 main categories: T−B− severe combined immunodeficiency, Omenn syndrome, and combined immunodeficiency. All patients showed a block in the precursor B-cell development, low B- and T-cell numbers, normal immunoglobulin gene use, limited B- and T-cell repertoires, and slightly impaired receptor editing.ConclusionThis study demonstrates that similar RAG mutations can result in similar immunobiological effects but different clinical phenotypes, indicating that the level of residual recombinase activity is not the only determinant for clinical outcome. We postulate a model in which the type and moment of antigenic pressure affect the clinical phenotypes of these patients. V(D)J recombination takes place during lymphocyte development to generate a large repertoire of T- and B-cell receptors. Mutations in recombination-activating gene 1 (RAG1) and RAG2 result in loss or reduction of V(D)J recombination. It is known that different mutations in RAG genes vary in residual recombinase activity and give rise to a broad spectrum of clinical phenotypes. We sought to study the immunologic mechanisms causing the clinical spectrum of RAG deficiency. We included 22 patients with similar RAG1 mutations (c.519delT or c.368_369delAA) resulting in N-terminal truncated RAG1 protein with residual recombination activity but presenting with different clinical phenotypes. We studied precursor B-cell development, immunoglobulin and T-cell receptor repertoire formation, receptor editing, and B- and T-cell numbers. Clinically, patients were divided into 3 main categories: T−B− severe combined immunodeficiency, Omenn syndrome, and combined immunodeficiency. All patients showed a block in the precursor B-cell development, low B- and T-cell numbers, normal immunoglobulin gene use, limited B- and T-cell repertoires, and slightly impaired receptor editing. This study demonstrates that similar RAG mutations can result in similar immunobiological effects but different clinical phenotypes, indicating that the level of residual recombinase activity is not the only determinant for clinical outcome. We postulate a model in which the type and moment of antigenic pressure affect the clinical phenotypes of these patients." @default.
• W2033926666 created "2016-06-24" @default.
• W2033926666 creator A5005040866 @default.
• W2033926666 creator A5006790084 @default.
• W2033926666 creator A5010499673 @default.
• W2033926666 creator A5019950150 @default.
• W2033926666 creator A5024394710 @default.
• W2033926666 creator A5030475189 @default.
• W2033926666 creator A5037086699 @default.
• W2033926666 creator A5038742233 @default.
• W2033926666 creator A5043968197 @default.
• W2033926666 creator A5047436272 @default.
• W2033926666 creator A5063101725 @default.
• W2033926666 creator A5069107002 @default.
• W2033926666 creator A5076709979 @default.
• W2033926666 creator A5076842465 @default.
• W2033926666 creator A5082860168 @default.
• W2033926666 creator A5082905763 @default.
• W2033926666 date "2014-04-01" @default.
• W2033926666 modified "2023-10-11" @default.
• W2033926666 title "Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes" @default.
• W2033926666 cites W135571511 @default.
• W2033926666 cites W1540664732 @default.
• W2033926666 cites W1574482841 @default.
• W2033926666 cites W1583240815 @default.
• W2033926666 cites W1963966256 @default.
• W2033926666 cites W1967674946 @default.
• W2033926666 cites W1972070781 @default.
• W2033926666 cites W1972313386 @default.
• W2033926666 cites W1980574246 @default.
• W2033926666 cites W1980715668 @default.
• W2033926666 cites W1989906917 @default.
• W2033926666 cites W1996073092 @default.
• W2033926666 cites W1996120882 @default.
• W2033926666 cites W1999687988 @default.
• W2033926666 cites W2001784394 @default.
• W2033926666 cites W2005942970 @default.
• W2033926666 cites W2014081607 @default.
• W2033926666 cites W2020094108 @default.
• W2033926666 cites W2029545121 @default.
• W2033926666 cites W2032874501 @default.
• W2033926666 cites W2039518116 @default.
• W2033926666 cites W2041877620 @default.
• W2033926666 cites W2070109046 @default.
• W2033926666 cites W2076198413 @default.
• W2033926666 cites W2084286364 @default.
• W2033926666 cites W2100462578 @default.
• W2033926666 cites W2103197942 @default.
• W2033926666 cites W2116718924 @default.
• W2033926666 cites W2116909043 @default.
• W2033926666 cites W2118399795 @default.
• W2033926666 cites W2123289499 @default.
• W2033926666 cites W2124173719 @default.
• W2033926666 cites W2128379811 @default.
• W2033926666 cites W2136482257 @default.
• W2033926666 cites W2147125897 @default.
• W2033926666 cites W2152218579 @default.
• W2033926666 cites W2155246914 @default.
• W2033926666 cites W2158266834 @default.
• W2033926666 cites W2158508385 @default.
• W2033926666 cites W2161645441 @default.
• W2033926666 cites W2411421886 @default.
• W2033926666 cites W4238006426 @default.
• W2033926666 cites W4244838338 @default.
• W2033926666 doi "https://doi.org/10.1016/j.jaci.2013.11.028" @default.
• W2033926666 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7112318" @default.
• W2033926666 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24418478" @default.
• W2033926666 hasPublicationYear "2014" @default.
• W2033926666 type Work @default.
• W2033926666 sameAs 2033926666 @default.
• W2033926666 citedByCount "54" @default.
• W2033926666 countsByYear W20339266662014 @default.
• W2033926666 countsByYear W20339266662015 @default.
• W2033926666 countsByYear W20339266662016 @default.
• W2033926666 countsByYear W20339266662017 @default.
• W2033926666 countsByYear W20339266662018 @default.
• W2033926666 countsByYear W20339266662019 @default.
• W2033926666 countsByYear W20339266662020 @default.
• W2033926666 countsByYear W20339266662021 @default.
• W2033926666 countsByYear W20339266662022 @default.
• W2033926666 countsByYear W20339266662023 @default.
• W2033926666 crossrefType "journal-article" @default.
• W2033926666 hasAuthorship W2033926666A5005040866 @default.
• W2033926666 hasAuthorship W2033926666A5006790084 @default.
• W2033926666 hasAuthorship W2033926666A5010499673 @default.
• W2033926666 hasAuthorship W2033926666A5019950150 @default.
• W2033926666 hasAuthorship W2033926666A5024394710 @default.
• W2033926666 hasAuthorship W2033926666A5030475189 @default.
• W2033926666 hasAuthorship W2033926666A5037086699 @default.
• W2033926666 hasAuthorship W2033926666A5038742233 @default.
• W2033926666 hasAuthorship W2033926666A5043968197 @default.
• W2033926666 hasAuthorship W2033926666A5047436272 @default.
• W2033926666 hasAuthorship W2033926666A5063101725 @default.
• W2033926666 hasAuthorship W2033926666A5069107002 @default.
• W2033926666 hasAuthorship W2033926666A5076709979 @default.
• W2033926666 hasAuthorship W2033926666A5076842465 @default.
• W2033926666 hasAuthorship W2033926666A5082860168 @default.
• W2033926666 hasAuthorship W2033926666A5082905763 @default.

• next